References
Williams RB. Do benzodiazepines have a role in the prevention or treatment of coronary heart disease and other medical disorders? J Psychiatry Res 1990; 24: 51–6
Yamawaki S. The use and development of anxiolytics in Japan. Eur Neuropsychopharmacol 1999; 9: S413–9
Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982; 43: 103–7
Lucki I, Rickels K, Giesecke MA, et al. Differential effects of the anxiolytic drugs, diazepam and buspirone, on memory function. Br J Clin Pharmacol 1987; 23: 207–11
Murphy SM, Owen RT, Tyrer PJ. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks’ treatment with diazepam or buspirone. Br J Psychiatry 1989; 154: 529–34
Jacobson AF, Dominguez RA, Goldstein BJ, et al. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 1985; 5: 290–6
Hamik A, Oksenberg G, Fischette C, et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990; 28: 99–109
Tanaka H, Shimizu H, Kumasaka Y, et al. Autoradiographic localization and pharmacological characterization of [3H]tandospirone binding sites in the rat brain. Brain Res 1991; 546: 181–9
Suzuki M, Uchiumi M, Murasaki M. Effects of tandospirone, a 5-HT1a receptor related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam. Jpn J Psychopharmacol 1993; 13: 213–24
Evance SM, Troisi JR, Griffiths RR. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 1994; 271: 683–94
Murasaki M, Mori A, Endo S, et al. Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis: a comparative double-blind study with diazepam [in Japanese with abstract in English]. Clin Eval 1992; 20: 295–329
Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry 2001; 49: 861–8
Oshima T, Kasuya Y, Terazawa E, et al. The anxiolytic effects of the 5-hydroxytryptamine-1A agonist tandospirone before otolaryngologic surgery. Anesth Analg 2001; 93: 1214–6
American Psychiatric Association. Diagnosis and statistical manual of mental disorders, fourth ed. Washington DC: American Psychiatric Association, 1994
Zinbarg RE, Barlow DH, Liebowitz M, et al. The DSM-IV field trial for mixed anxiety-depression. Am J Psychiatry 1994; 151: 1153–62
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5
Stahl SM. Classical antidepressants, serotonin selective reuptake inhibitors and noradrenergic reuptake inhibitors. In: Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. Cambridge: Cambridge University Press, 2000: 199–243
Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749–56
Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43: 81–6
Newton RE, Casten GP, Alms DR, et al. The side effect profile of buspirone in comparison to active controls and placebo. J Clin Psychiatry 1982; 43: 100–2
Wittchen H-U, Zhao S, Kessler R, et al. DSM-III-R generalized anxiety disorder in the national co-morbidity survey. Arch Gen Psychiatry 1994; 51: 355–64
Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54: 269–71
Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998; 18: 465–9
Acknowledgements
The authors would like to thank Ms Naoko Kinukawa, Department of Medical Information Science, and Ms Kayoko Yamamoto, Department of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan, for discussions and comments. There was no external funding for this study, and the authors have no conflicts of interest directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nishitsuji, K., To, H., Murakami, Y. et al. Tandospirone in the Treatment of Generalised Anxiety Disorder and Mixed Anxiety-Depression. Clin. Drug Investig. 24, 121–126 (2004). https://doi.org/10.2165/00044011-200424020-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200424020-00007